Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort ; volume:12 ; number:1 ; day:23 ; month:8 ; year:2012 ; pages:1-7 ; date:12.2012
BMC cancer ; 12, Heft 1 (23.8.2012), 1-7, 12.2012
- Creator
-
Dankner, Rachel
- Contributor
-
Balicer, Ran
Boffetta, Paolo
Boker, Lital Keinan
Wallenstein, Sylvan
Freedman, Laurence
Goldfracht, Margalit
Roth, Jesse
Tamler, Ronald
LeRoith, Derek
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-364
- URN
-
urn:nbn:de:1111-201603044029
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dankner, Rachel
- Balicer, Ran
- Boffetta, Paolo
- Boker, Lital Keinan
- Wallenstein, Sylvan
- Freedman, Laurence
- Goldfracht, Margalit
- Roth, Jesse
- Tamler, Ronald
- LeRoith, Derek
- SpringerLink (Online service)
Other Objects (12)
Cardiovascular outcome trials of glucose-lowering medications: an update
Inverse association between glucose-lowering medications and severe hyponatremia: a Swedish population-based case-control study
Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Diabetes, bone and glucose-lowering agents: basic biology
Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies : a meta-analysis based on cardiovascular outcomes trials
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes
Cardiovascular outcome trials of glucose-lowering medications: an update
Inverse association between glucose-lowering medications and severe hyponatremia: a Swedish population-based case-control study
Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Diabetes, bone and glucose-lowering agents: basic biology
Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies : a meta-analysis based on cardiovascular outcomes trials
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes
Cardiovascular outcome trials of glucose-lowering medications: an update
Inverse association between glucose-lowering medications and severe hyponatremia: a Swedish population-based case-control study
Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Diabetes, bone and glucose-lowering agents: basic biology
Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies : a meta-analysis based on cardiovascular outcomes trials
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes